Analysts expect Anebulo Pharmaceuticals, Inc. to report revenue of 0.00 for Q4 25, against a range of 0.00 to 0.00. The most recent reported quarter, Q3 25, came in at 0.00.
| Metric | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | |||||||||
| High Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.46 M | 4.62 M | 5.28 M | 4.49 M | 6.47 M | 7.01 M | 8.58 M | |||||||||
| Low Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.17 M | 3.82 M | 4.93 M | 4.00 M | 5.98 M | 6.26 M | 7.59 M | |||||||||
| Consensus Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.31 M | 4.22 M | 5.10 M | 4.24 M | 6.23 M | 6.63 M | 8.08 M |
Analysts expect Anebulo Pharmaceuticals, Inc. to report earnings per share of -0.15 for Q3 26, against a range of -0.16 to -0.14. The most recent reported quarter, Q2 26, came in at -0.05, a 58.3% beat against the -0.12 consensus.
| Metric | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.05 | -0.08 | -0.09 | -0.04 | -0.05 | -0.05 | -0.05 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -0.09 | -0.05 | -0.08 | -0.05 | -0.06 | -0.11 | -0.12 | -0.14 | -0.09 | -0.09 | -0.10 | -0.11 | -0.10 | -0.11 | -0.11 | ||||||||||
| Low Estimate | -0.11 | -0.05 | -0.08 | -0.05 | -0.08 | -0.13 | -0.12 | -0.16 | -0.11 | -0.11 | -0.12 | -0.13 | -0.12 | -0.13 | -0.13 | ||||||||||
| Consensus Estimate | -0.10 | -0.05 | -0.08 | -0.05 | -0.07 | -0.12 | -0.12 | -0.15 | -0.10 | -0.10 | -0.11 | -0.12 | -0.11 | -0.12 | -0.12 |